ResearcherYamaguchi UniversityActive in the last 2 years
Hidekazu Tanaka
Matched on ORCID iD 0000-0002-8673-5707; OpenAlex author ID A5077293109. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 30
2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper
Papers 7
- Survival Analysis of 4 Different Age Groups of Pancreatic Ductal Adenocarcinoma After Radical Resection From Retrospective Multi-Center Analysis (YPB-003). Co-author DOI 10.1002/cam4.70647↗
- Association of pancreatic atrophy patterns with intraductal extension of early pancreatic ductal adenocarcinoma: a multicenter retrospective study. Co-author DOI 10.1007/s00535-024-02149-0↗
- Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001). Co-author DOI 10.1097/mpa.0000000000002323↗
- Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy. Co-author DOI 10.1007/s10147-023-02396-w↗
- Utility of contrast-enhanced harmonic EUS for diagnosis of portal vein invasion by pancreatic cancer. Co-author DOI 10.4103/eus-d-21-00185↗
- Analysis of Progression Time in Pancreatic Cancer including Carcinoma In Situ Based on Magnetic Resonance Cholangiopancreatography Findings. Co-author DOI 10.3390/diagnostics11101858↗
- Contrast-enhanced harmonic endoscopic ultrasonography for evaluating the response to chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.dld.2019.03.015↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mamoru Takenaka · 5 shared papers, 2019–2024 · strength 0.63
- Paper Association of pancreatic atrophy patterns with intraductal extension of early pancreatic ductal adenocarcinoma: a mult… DOI 10.1007/s00535-024-02149-0↗
- Paper Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemoth… DOI 10.1007/s10147-023-02396-w↗
- Paper Utility of contrast-enhanced harmonic EUS for diagnosis of portal vein invasion by pancreatic cancer. DOI 10.4103/eus-d-21-00185↗
- Kosuke Minaga · 4 shared papers, 2019–2023 · strength 0.46
- Paper Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemoth… DOI 10.1007/s10147-023-02396-w↗
- Paper Utility of contrast-enhanced harmonic EUS for diagnosis of portal vein invasion by pancreatic cancer. DOI 10.4103/eus-d-21-00185↗
- Paper Analysis of Progression Time in Pancreatic Cancer including Carcinoma In Situ Based on Magnetic Resonance Cholangiopanc… DOI 10.3390/diagnostics11101858↗
- Ken Kamata · 4 shared papers, 2019–2023 · strength 0.46
- Paper Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemoth… DOI 10.1007/s10147-023-02396-w↗
- Paper Utility of contrast-enhanced harmonic EUS for diagnosis of portal vein invasion by pancreatic cancer. DOI 10.4103/eus-d-21-00185↗
- Paper Analysis of Progression Time in Pancreatic Cancer including Carcinoma In Situ Based on Magnetic Resonance Cholangiopanc… DOI 10.3390/diagnostics11101858↗
- Kentaro Yamao · 4 shared papers, 2019–2023 · strength 0.46
- Paper Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemoth… DOI 10.1007/s10147-023-02396-w↗
- Paper Utility of contrast-enhanced harmonic EUS for diagnosis of portal vein invasion by pancreatic cancer. DOI 10.4103/eus-d-21-00185↗
- Paper Analysis of Progression Time in Pancreatic Cancer including Carcinoma In Situ Based on Magnetic Resonance Cholangiopanc… DOI 10.3390/diagnostics11101858↗
- Masatoshi Kudo · 4 shared papers, 2019–2023 · strength 0.46
- Paper Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemoth… DOI 10.1007/s10147-023-02396-w↗
- Paper Utility of contrast-enhanced harmonic EUS for diagnosis of portal vein invasion by pancreatic cancer. DOI 10.4103/eus-d-21-00185↗
- Paper Analysis of Progression Time in Pancreatic Cancer including Carcinoma In Situ Based on Magnetic Resonance Cholangiopanc… DOI 10.3390/diagnostics11101858↗
- Yoshitaro Shindo · 2 shared papers, 2024–2025 · strength 0.37
- Paper Survival Analysis of 4 Different Age Groups of Pancreatic Ductal Adenocarcinoma After Radical Resection From Retrospect… DOI 10.1002/cam4.70647↗
- Paper Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001). DOI 10.1097/mpa.0000000000002323↗
- Tatsuya Ioka · 2 shared papers, 2024–2025 · strength 0.37
- Paper Survival Analysis of 4 Different Age Groups of Pancreatic Ductal Adenocarcinoma After Radical Resection From Retrospect… DOI 10.1002/cam4.70647↗
- Paper Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001). DOI 10.1097/mpa.0000000000002323↗
- Masao Nakajima · 2 shared papers, 2024–2025 · strength 0.37
- Paper Survival Analysis of 4 Different Age Groups of Pancreatic Ductal Adenocarcinoma After Radical Resection From Retrospect… DOI 10.1002/cam4.70647↗
- Paper Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001). DOI 10.1097/mpa.0000000000002323↗
- Taro Takami · 2 shared papers, 2024–2025 · strength 0.37
- Paper Survival Analysis of 4 Different Age Groups of Pancreatic Ductal Adenocarcinoma After Radical Resection From Retrospect… DOI 10.1002/cam4.70647↗
- Paper Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001). DOI 10.1097/mpa.0000000000002323↗
- Hiroaki Nagano · 2 shared papers, 2024–2025 · strength 0.37
- Paper Survival Analysis of 4 Different Age Groups of Pancreatic Ductal Adenocarcinoma After Radical Resection From Retrospect… DOI 10.1002/cam4.70647↗
- Paper Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001). DOI 10.1097/mpa.0000000000002323↗
- Kimikazu Hamano · 2 shared papers, 2024–2025 · strength 0.37
- Paper Survival Analysis of 4 Different Age Groups of Pancreatic Ductal Adenocarcinoma After Radical Resection From Retrospect… DOI 10.1002/cam4.70647↗
- Paper Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001). DOI 10.1097/mpa.0000000000002323↗
- Hiroto Matsui Matsui · 2 shared papers, 2024–2025 · strength 0.37
- Paper Survival Analysis of 4 Different Age Groups of Pancreatic Ductal Adenocarcinoma After Radical Resection From Retrospect… DOI 10.1002/cam4.70647↗
- Paper Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001). DOI 10.1097/mpa.0000000000002323↗
- Yasuo Otsuka · 2 shared papers, 2022–2023 · strength 0.28
- Atsushi Nakai · 2 shared papers, 2019–2022 · strength 0.20
- Katsuyoshi Ito · 1 shared paper, 2024 · strength 0.17
- Masahiro Tsujimae · 1 shared paper, 2024 · strength 0.16
- Keitaro Sofue · 1 shared paper, 2024 · strength 0.16
- Ryota Nakano · 1 shared paper, 2024 · strength 0.16
- Atsuhiro Masuda · 1 shared paper, 2024 · strength 0.16
- Takashi Kobayashi · 1 shared paper, 2024 · strength 0.16
- Hirochika Toyama · 1 shared paper, 2024 · strength 0.16
- Arata Sakai · 1 shared paper, 2024 · strength 0.16
- Tomoo Itoh · 1 shared paper, 2024 · strength 0.16
- Mika Miki · 1 shared paper, 2024 · strength 0.16
- Yuzo Kodama · 1 shared paper, 2024 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.